The Institut Pasteur and Moderna have signed a Master Material Transfer Agreement (MMTA) to enable researchers of the Institut Pasteur to have access to Moderna's preclinical manufacturing capabilities and its research and development expertise.
The objective is to jointly explore the possibility of mRNA to tackle the world's greatest global public health threats.
Institut Pasteur researchers will be able to use Moderna mRNA production capabilities to explore novel antigen designs and accelerate vaccines development (https://mrna-access.modernatx.com/).
Through this program, Moderna allows their partners to take advantage of the flexibility afforded by their platform to develop novel mRNA medicines for emerging and neglected infectious diseases.
